Literature DB >> 2723693

Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions.

O S Miettinen1, J J Caro.   

Abstract

The risk of a particular kind of adverse reaction to a particular agent must be thought of with reference to the contemplated type of exposure and the type of person potentially exposed, and critically important in the contemplated exposure is its duration. In the general case, a distinction has to be made between risk during exposure and that after its discontinuation. For both of these risks, modifications of their magnitudes especially by previous exposure to the same agent must be considered. These risks are studied by focusing on incidence densities specific to subintervals of the total periods of risk. Assessment of these densities is generally best accomplished by following a (very large) dynamic (open) population, not specified on the basis of exposure. Cases of the adverse event, without regard for their etiology, that occur in this source population over the period of follow-up need to be identified and classified, first as to whether they arose from the study population proper or from the extraneous segment of the source population. Those arising from the study population and characterized by "recent" exposure--implying potential causation by it--need to be classified according to the attained duration of exposure and, where applicable, time since its discontinuation at the time of the inception of the adverse event. An appropriate sample of the source population over its follow-up needs to be obtained and classified in like manner.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2723693     DOI: 10.1016/0895-4356(89)90037-1

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  10 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 2.  A pathway to improved prospective observational post-authorization safety studies.

Authors:  Victor A Kiri
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

3.  Exchangeability in the case-crossover design.

Authors:  Murray A Mittleman; Elizabeth Mostofsky
Journal:  Int J Epidemiol       Date:  2014-04-22       Impact factor: 7.196

4.  To use or not to use the odds ratio in epidemiologic analyses?

Authors:  M Nurminen
Journal:  Eur J Epidemiol       Date:  1995-08       Impact factor: 8.082

5.  Oral contraceptives and the risk of gallbladder disease: a meta-analysis.

Authors:  C Thijs; P Knipschild
Journal:  Am J Public Health       Date:  1993-08       Impact factor: 9.308

6.  Outcomes Following Ischemic Stroke in Older Patients With CKD Stages 4 and 5: A Retrospective Cohort Study.

Authors:  James B Wetmore; Charles A Herzog; Anne Sexter; David T Gilbertson; Jiannong Liu; Scott E Kasner
Journal:  Am J Kidney Dis       Date:  2020-05-28       Impact factor: 8.860

7.  Adverse events associated with prolonged antibiotic use.

Authors:  Sharon B Meropol; K Arnold Chan; Zhen Chen; Jonathan A Finkelstein; Sean Hennessy; Ebbing Lautenbach; Richard Platt; Stephanie D Schech; Deborah Shatin; Joshua P Metlay
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-05       Impact factor: 2.890

8.  Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies.

Authors:  George A Neyarapally; Tarek A Hammad; Simone P Pinheiro; Solomon Iyasu
Journal:  BMJ Open       Date:  2012-09-25       Impact factor: 2.692

9.  Testosterone treatment and risk of venous thromboembolism: population based case-control study.

Authors:  Carlos Martinez; Samy Suissa; Stephan Rietbrock; Anja Katholing; Ben Freedman; Alexander T Cohen; David J Handelsman
Journal:  BMJ       Date:  2016-11-30

10.  Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.

Authors:  Carlos Martinez; Christopher Wallenhorst; Stephan Rietbrock; Ben Freedman
Journal:  J Am Heart Assoc       Date:  2020-01-15       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.